Sirolimus as Primary Immunosuppression Attenuates Allograft Vasculopathy With Improved Late Survival and Decreased Cardiac Events After Cardiac Transplantation | Zendy

Yan Topilsky | Zendy; Tal Hasin | Zendy; Eugenia Raichlin | Zendy; Barry A. Boilson | Zendy; John A. Schirger | Zendy; Naveen L. Pereira | Zendy; Brooks S. Edwards | Zendy; Alfredo L. Clavell | Zendy; Richard J. Rodeheffer | Zendy; Robert P. Frantz | Zendy; Simon Maltais | Zendy; Soon J. Park | Zendy; Richard C. Daly | Zendy; Amir Lerman | Zendy; Sudhir S. Kushwaha | Zendy

Open Access

Sirolimus as Primary Immunosuppression Attenuates Allograft Vasculopathy With Improved Late Survival and Decreased Cardiac Events After Cardiac Transplantation

Author(s) -

Yan Topilsky,

Tal Hasin,

Eugenia Raichlin,

Barry A. Boilson,

John A. Schirger,

Naveen L. Pereira,

Brooks S. Edwards,

Alfredo L. Clavell,

Richard J. Rodeheffer,

Robert P. Frantz,

Simon Maltais,

Soon J. Park,

Richard C. Daly,

Amir Lerman,

Sudhir S. Kushwaha

Publication year - 2011

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.111.040360

Subject(s) - medicine , calcineurin , sirolimus , transplantation , intravascular ultrasound , heart transplantation , immunosuppression , ejection fraction , cardiology , urology , surgery , heart failure

We retrospectively analyzed the potential of sirolimus as a primary immunosuppressant in the long-term attenuation of cardiac allograft vasculopathy progression and the effects on cardiac-related morbidity and mortality.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research